Tim Watkins insider trades: Contineum Therapeutics (CTNM) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Tim reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | CTNM | ↓ Sell | 10,833 | $16.02 | $174K | Direct | Jul 1, 2026 (1d) |
| Mar 2, 2026 | CTNM | ↓ Sell | 3,611 | $15.02 | $54K | Direct | Mar 2, 2026 (0d) |
| Jan 28, 2026 | CTNM | ↓ Sell | 3,611 | $14.18 | $51K | Direct | Jan 30, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CTNM insiders
Open-market trades in the last 12 months
About Tim Watkins's insider trades
Tim Watkins is CMO & Head of Development at Contineum Therapeutics (CTNM). Since Jan 28, 2026, Tim has reported no open-market purchases and 3 sales worth $279K on SEC Form 4. In the last 12 months: 3 sales ($279K).
Their filings also include option exercises (3 filings), grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CTNM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.